Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prolyl-tRNA synthetase inhibitor as a novel first-in-class keloid treatment: downregulation of de novo collagen synthesis and inflammatory cascade.

The British journal of dermatology·2025

Same author

Novel therapeutic strategy for intractable keloids: suppression of intracellular mechanotransduction and actin polymerization via Rho-kinase pathway inhibition.

The British journal of dermatology·2024

Same author

Posterior reversible encephalopathy syndrome following uneventful clipping of an unruptured intracranial aneurysm: A case report.

World journal of clinical cases·2023

Same author

Osteomyelitis.

JAAPA : official journal of the American Academy of Physician Assistants·2022

Same author

Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.

PLoS pathogens·2022

Same author

CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.

Frontiers in immunology·2021

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Biomarkers.

Joseph Hwang¹, Raad Gitan¹, Deborah Droll¹

¹MilliporeSigma, St. Louis, MO, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association

|December 24, 2025

Summary

A new high-sensitivity immunoassay accurately measures Alzheimer's Disease (AD) biomarkers Aβ42/Aβ40 in plasma. This multiplex assay offers improved differentiation between healthy individuals and AD patients, aiding in disease monitoring.

Area of Science:

Neuroscience
Biochemistry
Medical Diagnostics

Background:

Alzheimer's Disease (AD) affects millions globally, with aging populations increasing prevalence.
Current AD diagnostics rely on neurodegenerative biomarkers in blood.
Measuring the Aβ42/Aβ40 ratio is of interest, but requires highly sensitive immunoassays for blood detection.

Purpose of the Study:

To develop and verify a novel, high-sensitivity immunoassay for simultaneous quantitation of Aβ42 and Aβ40 in human plasma.
To evaluate the performance of this new assay in differentiating between healthy individuals and AD patients.

Main Methods:

Development of a novel SMC® Aβ42/Aβ40 high-sensitivity immunoassay kit.
Utilization of the FemtoQuest™ instrument for simultaneous biomarker measurement.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

Testing of human plasma samples from healthy and AD patients.

Main Results:

Singleplex assays confirmed detectable levels of Aβ42 and Aβ40, differentiating healthy from AD samples (p<0.05).
The multiplex assay simultaneously measured both biomarkers in the same samples.
The Aβ42/Aβ40 ratio demonstrated stronger differentiation between healthy and AD groups compared to individual biomarkers.

Conclusions:

Multiplex high-sensitivity technology is valuable for evaluating multiple biomarkers simultaneously.
The SMC® Aβ42/Aβ40 immunoassay kit is a potent non-invasive tool for monitoring neurodegenerative diseases like AD.
Further research on other biomarker ratios may reveal additional valuable AD diagnostic measures.